McCulloch M I, Burger H, Spearman C W N, Cooke L, Goddard E, Gajjar P, Numanoglu A, Rode H, Kahn D, Millar A J W
Red Cross Children's Hospital and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
Transplant Proc. 2005 Mar;37(2):1220-3. doi: 10.1016/j.transproceed.2004.12.223.
Drugs used for immunosuppression have been implicated in causing numerous long-term side effects including nephrotoxicity, glucose intolerance, and hyperlipidemia. In this study, we reviewed our pediatric liver transplant recipients in terms of glomerular filtration rate (GFR) as well as fasting glucose and lipid profiles. To date, 79 pediatric liver transplantations have been performed at our center: 24 transplantations of at least 5 months to a maximum of 7.3 years posttransplant are reviewed herein. The mean time posttransplantation was 2.1 years. Nine boys and 15 girls showed a distribution of 19 mixed race, 3 black, and 2 white patients. The mean age at the time of transplantation was 6.6 years (0.8-13.3 years) with 8 cases under the age of 3 years. All recipients started with Cyclosporine Neoral (CSA) as first line, but, at the time of testing, immunosuppression included 5 children on CSA and 19 on Tacrolimus. Radionuclide 51 Cr-EDTA Glomerular Filtration Rates (GFR) showed a range from 21 to 220 mL/min/1.73 m2 (mean 96.1, median 89.8). Seven cases had a GFR less than 75 mL/min/1.73 m2. Twenty-one children were on antihypertensives agents: 15 children on 1 agent and 6 children on 2 agents. On full fasting lipid profiles, the total cholesterol ranged from 2 to 7.9 mmol/L (mean 4.4). Only 1 child is currently on statin therapy. Fasting glucose ranged from 3.2 to 5.9 mmol/L (mean 4.1) No difference was observed in glucose values between CsA and Tacrolimus. Thus, immunosuppressive therapies, such as the calcineurin inhibitors, are known to cause nephrotoxicity, which is of concern in pediatric liver transplant recipients. Almost all our patients currently require antihypertensive therapy. At present, the renal function is adequate in the majority of the group, but this study needs to be extended to other pediatric liver transplant recipients with particular emphasis on those who are more than 5 years posttransplantation.
用于免疫抑制的药物已被认为会导致许多长期副作用,包括肾毒性、葡萄糖耐受不良和高脂血症。在本研究中,我们根据肾小球滤过率(GFR)以及空腹血糖和血脂水平对我们的小儿肝移植受者进行了评估。迄今为止,我们中心已进行了79例小儿肝移植手术:本文回顾了24例移植后至少5个月至最长7.3年的移植手术。移植后的平均时间为2.1年。9名男孩和15名女孩,分布为19名混血儿、3名黑人、2名白人患者。移植时的平均年龄为6.6岁(0.8 - 13.3岁),其中8例年龄在3岁以下。所有受者均以新山地明(环孢素,CSA)作为一线用药,但在检测时,免疫抑制治疗包括5名使用CSA的儿童和19名使用他克莫司的儿童。放射性核素51铬 - 乙二胺四乙酸肾小球滤过率(GFR)显示范围为21至220毫升/分钟/1.73平方米(平均96.1,中位数89.8)。7例患者的GFR低于75毫升/分钟/1.73平方米。21名儿童正在服用抗高血压药物:15名儿童服用1种药物,6名儿童服用2种药物。在全空腹血脂水平方面,总胆固醇范围为2至7.9毫摩尔/升(平均4.4)。目前只有1名儿童正在接受他汀类药物治疗。空腹血糖范围为3.2至5.9毫摩尔/升(平均4.1)。在CSA和他克莫司之间未观察到血糖值的差异。因此,已知诸如钙调神经磷酸酶抑制剂等免疫抑制疗法会导致肾毒性,这在小儿肝移植受者中是一个值得关注的问题。我们几乎所有的患者目前都需要抗高血压治疗。目前,该组大多数患者的肾功能是足够的,但本研究需要扩展到其他小儿肝移植受者,尤其要重点关注那些移植后超过5年的患者。